Top Trends Transforming the Direct Oral Anticoagulants (DOACs) Device Market Landscape in 2025: Innovative Automated Assays Enhance Accuracy And Efficiency In Anticoagulant Monitoring

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Direct Oral Anticoagulants (DOACs) Device Industry Market Size Be by 2025?
Over the past few years, the market size for direct oral anticoagulants (DOACs) devices has seen significant expansion. A rise from $30.10 billion in 2024 to $32.80 billion in 2025 is projected, representing a compound annual growth rate (CAGR) of 9.0%. The historical growth can be attributed to various factors including an increase in cardiovascular disease cases, a surge in atrial fibrillation incidents, heightened awareness on stroke prevention, a growth in anticoagulant prescriptions and a booming elderly population.

What's the Long-Term Growth Forecast for the Direct Oral Anticoagulants (DOACs) Device Market Size Through 2029?
In the coming years, a significant increase in the market size of direct oral anticoagulants (DOACs) devices is anticipated. The market is forecasted to attain a value of $45.65 billion in 2029, with a compound annual growth rate (CAGR) of 8.6%. The predicted growth in this period can be attributed to multiple factors, including the rising adoption of personalized medicine, the increasing inclination towards home-based anticoagulant management, a surge in demand for quick diagnostic instruments, heightened awareness concerning stroke prevention, and the expansion of healthcare infrastructure in emerging markets. Key trends during the forecast timeline encompass the incorporation of intelligent sensors in monitoring devices, the creation of point-of-care direct oral anticoagulant testing tools, ongoing innovation in drug delivery mechanisms, integration into standard clinical workflows, and advancements in technology related to patient compliance tools.

View the full report here:
https://www.thebusinessresearchcompany.com/report/direct-oral-anticoagulants-doacs-device-global-market-report

What Are the Key Growth Drivers Fueling the Direct Oral Anticoagulants (DOACs) Device Market Expansion?
The escalating occurrence of cardiovascular conditions is forecasted to stimulate the expansion of the direct oral anticoagulants (DOACs) device market in the future. When we speak about cardiovascular issues, we're talking about a variety of diseases that affect the heart and vessels, frequently resulting in complications like heart attacks, strokes, or other circulatory system-related problems. The rise in cardiovascular diseases is attributed to the growing prevalence of inactive lifestyles, which can lead to weight gain, increased blood pressure, and a gradual deterioration of cardiovascular health. Direct oral anticoagulants (DOACs) play a crucial role in managing these illnesses by effectively reducing stroke and blood clot risks among atrial fibrillation patients, ensuring dependable anticoagulation without the need for regular blood tests. For example, the American Heart Association reported that in 2022, cardiovascular diseases were responsible for 941,652 deaths in the US, over 10,000 more than the 931,578 deaths recorded in 2021. As a result, the rising occurrence of cardiovascular diseases is spurring the expansion of the direct oral anticoagulants (DOACs) device market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp

Which Emerging Trends Are Transforming the Direct Oral Anticoagulants (DOACs) Device Market in 2025?
Key entities in the direct oral anticoagulants (DOACs) market are prioritizing the innovation of state-of-the-art solutions including automated coagulation assays. The aim is to bolster the precision, effectiveness, and uniformity of DOAC level monitoring in clinical labs. Automated coagulation assays are machine-conducted laboratory procedures that gauge blood clotting speed to aid in detecting bleeding or clotting problems. For instance, Roche Holding AG, based in Switzerland, introduced three specialized coagulation tests for Factor Xa inhibitors in February 2024. These tests expand doctors' capacity to correctly assess the anticoagulation condition of patients on direct Factor Xa inhibitors like rivaroxaban and apixaban. They contribute to clinical decision making through the exact quantification of the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios such as bleeding, overdose, or immediate surgery. By employing Roche's reagent cassette technology on cobas t analyzers, these automated assays yield superior results, reduce manual operations, and boost laboratory workflow productivity.

How Is the Direct Oral Anticoagulants (DOACs) Device Market Segmented?
The direct oral anticoagulants (DOACs) device market covered in this report is segmented

1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users

Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp

Which Companies Are Leading the Charge in Direct Oral Anticoagulants (DOACs) Device Market Innovation?
Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy's Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.

Which Regions Are Leading the Global Direct Oral Anticoagulants (DOACs) Device Market in Revenue?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27281

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.